Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

9.250 -0.530 (-5.42%)
Streaming Delayed Price Updated: 3:38 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
2 Cathie Wood Stocks With Jaw-Dropping Growth Potential
These two platform biotechs could revolutionize the field of biologically based products. 
Via The Motley Fool
Cathie Wood Just Bought These 3 Biotech Stocks. Should You?
They aren't all long shots, but they're all innovative. 
Via The Motley Fool
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
Via Benzinga
Cathie Wood's Ark Loads Up On $3.3M Worth Of Robinhood Shares, Continues Its Tesla Stock Purchase Spree
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week
Wood added to her existing positions in these three exciting companies. 
Via The Motley Fool
Evaluating Ginkgo Bioworks Holdings: Insights From 4 Financial Analysts
Via Benzinga
2 Cathie Wood Stocks That Might Be Smart Buys Right Now
These two biotech stocks hold enormous potential. 
Via The Motley Fool
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Outlook For Ginkgo Bioworks Holdings
Via Benzinga
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
From bit.bio
Via Business Wire
Is Ginkgo Bioworks Stock a Buy Now?
Ginkgo Bioworks says it is experiencing strong growth from its biopharma customers. 
Via The Motley Fool
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
These two businesses have viable paths to making investors richer -- possibly soon. 
Via The Motley Fool
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You won't find many timid bets among the Cathie Wood stocks she believes will dramatically alter our future. 
Via InvestorPlace
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
Expectations for these stocks are sky-high, but so are the risks. 
Via The Motley Fool
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought This Week
The widely followed growth stock investor is adding to some of her holdings this week. 
Via The Motley Fool
NuStar Energy, Spirit Airlines, Fastly And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Monday. Shares of NuStar Energy L.P. (NYSE: NS) rose sharply during Monday’s session after Sunoco announced it will... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
Via Benzinga
3 Pricey Stocks I'll Be Watching Like a Hawk in 2024
Good things come to those who wait. 
Via The Motley Fool
Flexsteel Industries Posts Strong Preliminary Results, Joins Wipro, Sify Technologies And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. 
Via Benzinga
3 Cathie Wood Stocks to Start Off Your New Year Right
The following stocks could deliver big gains over time. 
Via The Motley Fool
Better Growth Investment: Ginkgo Bioworks vs. Shiba Inu
Both of these investments need to prove that they can actually grow. 
Via The Motley Fool
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. 
Via The Motley Fool
2 Growth Stocks That Could Rocket 149% to 210% Higher in 2024, According to Wall Street
Find out why investment bank analysts are hyperbullish for these stocks. 
Via The Motley Fool
5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
You'll find exciting innovators across industries. 
Via The Motley Fool
This Artificial Intelligence Stock Could Be Like Buying Amazon in 1997
Ginkgo Bioworks has frequently been compared to Amazon in the media. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Could Ginkgo Bioworks Stock Help You Become a Millionaire?
It's easy to see a way for this to be a huge business in the future, but the path ahead of it is by no means a smooth one. 
Via The Motley Fool
Tech Stocks Set New All-Time High, Small Caps On Fire As Wall Street Bulls Run Wild: What's Driving Markets Tuesday?
Tuesday, December 19, 2023, stands now as a remarkable day in Wall Street’s history, as the technology stocks of the Nasdaq 100 mark a significant milestone, surging to new highs after a hiatus of 758... 
Via Benzinga
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Biotech stocks have had a tough run in 2023 so far. As of early November, the iShares Biotechnology ETF (IBB) was down 7.5% while the S&P 500 was up more than 14%. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.